241 related articles for article (PubMed ID: 36670155)
1. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.
Stenberg E; Näslund E
Int J Obes (Lond); 2023 Apr; 47(4):251-256. PubMed ID: 36670155
[TBL] [Abstract][Full Text] [Related]
2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
3. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
[TBL] [Abstract][Full Text] [Related]
4. Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
Pasternak B; Wintzell V; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Svanström H; Ueda P
Diabetes Care; 2020 Jun; 43(6):1326-1335. PubMed ID: 32295809
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
8. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
14. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
[TBL] [Abstract][Full Text] [Related]
16. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
Giugliano D; Scappaticcio L; Longo M; Caruso P; Maiorino MI; Bellastella G; Ceriello A; Chiodini P; Esposito K
Cardiovasc Diabetol; 2021 Sep; 20(1):189. PubMed ID: 34526024
[TBL] [Abstract][Full Text] [Related]
18. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]